Skip to main content
Erschienen in: American Journal of Clinical Dermatology 1/2019

01.02.2019 | Systematic Review

Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis

verfasst von: Hsi Yen, Ching-Chi Chi

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The relationship between psoriasis and vitiligo has not been previously confirmed, and we therefore aimed to investigate this association.

Methods

We conducted a search of the MEDLINE and EMBASE electronic databases on 22 January 2018 for case–control, cross-sectional, and cohort studies examining the association between psoriasis and vitiligo. A customized Newcastle–Ottawa Scale was used to assess the risk of bias of the included studies. We performed a random effects meta-analysis to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs) for case–control and cross-sectional studies.

Results

Of 2453 citations identified from the literature search, 10 case–control/cross-sectional studies with a total of 120,866 psoriasis cases and 79,907 vitiligo cases were included in our study. Four of these studies were rated as high risk of bias. We found a significantly increased odds for vitiligo in psoriasis patients (summary OR 2.29, 95% CI 1.56–3.37, studies = 7), as well as a significantly elevated odds for psoriasis in vitiligo patients (summary OR 3.43, 95% CI 1.86–6.33, studies = 4).

Conclusions

Our meta-analysis showed that psoriasis and vitiligo are associated with each other. Several studies had a high risk of bias, and further investigation is needed to confirm this association and amplify treatment options.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Michalek I, Loring B, John S. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.CrossRefPubMed Michalek I, Loring B, John S. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12.CrossRefPubMed
2.
Zurück zum Zitat Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.CrossRefPubMed Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73.CrossRefPubMed
3.
Zurück zum Zitat Damiani G, Berti E, Pigatto P, Franchi C, Asa’ad F. Benchmarking stem cells and transplantation in psoriasis. J Stem Cell Res Ther. 2018;8(3):416. Damiani G, Berti E, Pigatto P, Franchi C, Asa’ad F. Benchmarking stem cells and transplantation in psoriasis. J Stem Cell Res Ther. 2018;8(3):416.
4.
Zurück zum Zitat Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.CrossRefPubMed Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.CrossRefPubMed
5.
Zurück zum Zitat Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.CrossRefPubMed Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.CrossRefPubMed
6.
Zurück zum Zitat Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.CrossRefPubMed Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.CrossRefPubMed
7.
Zurück zum Zitat Wu JJ, Nguyen TU, Poon KYT, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924–30.CrossRefPubMed Wu JJ, Nguyen TU, Poon KYT, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924–30.CrossRefPubMed
8.
Zurück zum Zitat Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40.CrossRefPubMed Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40.CrossRefPubMed
9.
Zurück zum Zitat Blegvad C, Egeberg A, Tind Nielsen TE, Gislason GH, Zachariae C, Nybo Andersen AM, et al. Autoimmune disease in children and adolescents with psoriasis: A cross-sectional study in Denmark. Acta Derm Venereol. 2017;97(10):1225–9.CrossRefPubMed Blegvad C, Egeberg A, Tind Nielsen TE, Gislason GH, Zachariae C, Nybo Andersen AM, et al. Autoimmune disease in children and adolescents with psoriasis: A cross-sectional study in Denmark. Acta Derm Venereol. 2017;97(10):1225–9.CrossRefPubMed
10.
Zurück zum Zitat Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151–7.CrossRefPubMed Radtke MA, Schäfer I, Glaeske G, Jacobi A, Augustin M. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151–7.CrossRefPubMed
12.
Zurück zum Zitat Zander N, Schäfer I, Radtke M, Jacobi A, Heigel H, Augustin M. Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. Arch Dermatol Res. 2017;309(5):349–56.CrossRefPubMed Zander N, Schäfer I, Radtke M, Jacobi A, Heigel H, Augustin M. Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. Arch Dermatol Res. 2017;309(5):349–56.CrossRefPubMed
13.
Zurück zum Zitat Chen YT, Chen YJ, Hwang CY, Lin MW, Chen TJ, Chen CC, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362–9.CrossRefPubMed Chen YT, Chen YJ, Hwang CY, Lin MW, Chen TJ, Chen CC, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol. 2015;29(7):1362–9.CrossRefPubMed
14.
Zurück zum Zitat Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015;56(3):719–25.CrossRefPubMedPubMedCentral Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J. 2015;56(3):719–25.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Teulings HE, Ceylan E, Overkamp M, Vrijman C, Bos JD, Nijsten TE, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years. Br J Dermatol. 2016;175(4):821–4.CrossRefPubMed Teulings HE, Ceylan E, Overkamp M, Vrijman C, Bos JD, Nijsten TE, et al. Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years. Br J Dermatol. 2016;175(4):821–4.CrossRefPubMed
16.
Zurück zum Zitat Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr Med Res Opin. 2006;22(5):989–1000.CrossRefPubMed Robinson D Jr, Hackett M, Wong J, Kimball AB, Cohen R, Bala M, et al. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr Med Res Opin. 2006;22(5):989–1000.CrossRefPubMed
17.
Zurück zum Zitat Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.PubMedPubMedCentral Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7–32.PubMedPubMedCentral
18.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.CrossRefPubMed Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.CrossRefPubMed
20.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMed
21.
Zurück zum Zitat Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
24.
Zurück zum Zitat Sawchuk M, Spano F, Loo WJ, Guenther L. The coexistence of psoriasis and vitiligo: a review. J Cutan Med Surg. 2012;16(5):300–5.CrossRefPubMed Sawchuk M, Spano F, Loo WJ, Guenther L. The coexistence of psoriasis and vitiligo: a review. J Cutan Med Surg. 2012;16(5):300–5.CrossRefPubMed
25.
26.
Zurück zum Zitat Zhernakova A, Van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10(1):43–55.CrossRefPubMed Zhernakova A, Van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10(1):43–55.CrossRefPubMed
27.
Zurück zum Zitat Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55(5):443–52.CrossRefPubMed Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55(5):443–52.CrossRefPubMed
28.
Zurück zum Zitat Martinon F, Gaide O, Pétrilli V, Mayor A, Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007;29(3):213–29.CrossRefPubMed Martinon F, Gaide O, Pétrilli V, Mayor A, Tschopp J. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007;29(3):213–29.CrossRefPubMed
29.
Zurück zum Zitat Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356(12):1216–25.CrossRefPubMed Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med. 2007;356(12):1216–25.CrossRefPubMed
30.
Zurück zum Zitat Carlström M, Ekman AK, Petersson S, Söderkvist P, Enerbäck C. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 2012;21(12):932–7.CrossRefPubMed Carlström M, Ekman AK, Petersson S, Söderkvist P, Enerbäck C. Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 2012;21(12):932–7.CrossRefPubMed
31.
Zurück zum Zitat Johansen C, Moeller K, Kragballe K, Iversen L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol. 2007;127(12):2857–64.CrossRefPubMed Johansen C, Moeller K, Kragballe K, Iversen L. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol. 2007;127(12):2857–64.CrossRefPubMed
32.
Zurück zum Zitat Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 expression is upregulated in lesional psoriatic skin. J Invest Dermatol. 2011;131(3):670–6.CrossRefPubMed Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 expression is upregulated in lesional psoriatic skin. J Invest Dermatol. 2011;131(3):670–6.CrossRefPubMed
33.
Zurück zum Zitat Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170(4):816–23.CrossRefPubMed Marie J, Kovacs D, Pain C, Jouary T, Cota C, Vergier B, et al. Inflammasome activation and vitiligo/nonsegmental vitiligo progression. Br J Dermatol. 2014;170(4):816–23.CrossRefPubMed
34.
Zurück zum Zitat Zhu K-J, Lv Y-M, Yin X-Y, Wang Z-X, Sun L-D, He S-M, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011;6(11):e23089.CrossRefPubMedPubMedCentral Zhu K-J, Lv Y-M, Yin X-Y, Wang Z-X, Sun L-D, He S-M, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. PLoS One. 2011;6(11):e23089.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.CrossRefPubMed Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–71.CrossRefPubMed
36.
Zurück zum Zitat Taher Z, Lauzon G, Maguiness S, Dytoc M. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol. 2009;161(3):654–9.CrossRefPubMed Taher Z, Lauzon G, Maguiness S, Dytoc M. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus. Br J Dermatol. 2009;161(3):654–9.CrossRefPubMed
37.
Zurück zum Zitat Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–50.CrossRefPubMed Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–50.CrossRefPubMed
38.
Zurück zum Zitat Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, et al. The role of IL-17 in vitiligo: a review. Autoimmun Rev. 2016;15(4):397–404.CrossRefPubMedPubMedCentral Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, et al. The role of IL-17 in vitiligo: a review. Autoimmun Rev. 2016;15(4):397–404.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2):256–60.CrossRefPubMed Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2):256–60.CrossRefPubMed
40.
Zurück zum Zitat Bassiouny D, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292–7.CrossRefPubMed Bassiouny D, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292–7.CrossRefPubMed
41.
Zurück zum Zitat Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology. 1996;193(1):65–6.CrossRefPubMed Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology. 1996;193(1):65–6.CrossRefPubMed
42.
Zurück zum Zitat Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon-induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010;49(7):829–33.CrossRefPubMed Hamadah I, Binamer Y, Sanai FM, Abdo AA, Alajlan A. Interferon-induced vitiligo in hepatitis C patients: a case series. Int J Dermatol. 2010;49(7):829–33.CrossRefPubMed
43.
Zurück zum Zitat Afshar M, Martinez A, Gallo R, Hata T. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27(6):771–8.CrossRefPubMed Afshar M, Martinez A, Gallo R, Hata T. Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad Dermatol Venereol. 2013;27(6):771–8.CrossRefPubMed
44.
Zurück zum Zitat Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38–47.CrossRefPubMed Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38–47.CrossRefPubMed
45.
Zurück zum Zitat Seçkin D, Durusoy Ç, Şahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21(5):577–9.CrossRefPubMed Seçkin D, Durusoy Ç, Şahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol. 2004;21(5):577–9.CrossRefPubMed
46.
Zurück zum Zitat Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol. 2008;20(4):401–7.CrossRefPubMed Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol. 2008;20(4):401–7.CrossRefPubMed
47.
Zurück zum Zitat Bertolotti A, Boniface K, Vergier B, Mossalayi D, Taieb A, Ezzedine K, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407.CrossRefPubMed Bertolotti A, Boniface K, Vergier B, Mossalayi D, Taieb A, Ezzedine K, et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407.CrossRefPubMed
49.
Zurück zum Zitat Kuo CM, Tung TH, Wang SH, Chi CC. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(3):355–62.CrossRefPubMed Kuo CM, Tung TH, Wang SH, Chi CC. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32(3):355–62.CrossRefPubMed
50.
Zurück zum Zitat Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton P. Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol. 2015;173(6):1544–5.CrossRefPubMed Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton P. Narrowband ultraviolet B phototherapy in psoriasis reduces proinflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol. 2015;173(6):1544–5.CrossRefPubMed
Metadaten
Titel
Association Between Psoriasis and Vitiligo: A Systematic Review and Meta-Analysis
verfasst von
Hsi Yen
Ching-Chi Chi
Publikationsdatum
01.02.2019
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 1/2019
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-018-0394-1

Weitere Artikel der Ausgabe 1/2019

American Journal of Clinical Dermatology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.